Salarius Pharmaceuticals (NASDAQ:SLRX) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Salarius Pharmaceuticals (NASDAQ:SLRX) from a sell rating to a hold rating in a report issued on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Salarius Pharmaceuticals Price Performance

Shares of SLRX opened at $0.83 on Friday. The stock has a market capitalization of $4.83 million, a PE ratio of -0.02 and a beta of 0.40. The business’s fifty day moving average price is $2.69 and its 200 day moving average price is $7.14. Salarius Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its earnings results on Friday, November 14th. The company reported ($1.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($33.60) by $31.79.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.